Literature DB >> 29392966

The PLIANT trial gives trustworthy data.

Bengt Glimelius1, Jan Kowalski2, Jacques Näsström3.   

Abstract

Year:  2018        PMID： 29392966     DOI： 10.1080/0284186X.2018.1433876

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  1 in total

1.  The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOx.

Authors:  Jan Olof G Karlsson; Per Jynge; Louis J Ignarro
Journal:  Antioxidants (Basel)       Date:  2021-12-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.